Spinraza – approved in the US in 2016 and Europe in 2017 – was the first disease-modifying therapy for SMA. It is an antisense oligonucleotide (ASO) designed to increase the production of ...

The global antisense oligonucleotides market is poised for remarkable growth over the next decade, projected to rise from USD 2,913.5 million in 2023 to USD 5,519.6 million by 2033 moving forward with ...